The efficacy and duration of vaccine protection against human papillomavirus;Effektivität und Dauer des Impfschutzes gegen humane Papillomviren: Systematische Literaturübersicht und Metaanalyse

Deutsches Arzteblatt International

Volumn 111, Issue 35-36, 2014, Pages

  Deleré, Yvonne ^a   Wichmann, Ole ^a   Klug, Stefanie J ^b   Van Der Sande, Marianne ^c   Terhardt, Martin ^d   Zepp, Fred ^e   Harder, Thomas ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Outpatient Clinic for Pediatric and Adolescent Medicine   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; FOLLOW UP; HUMAN; INFECTION PREVENTION; INFECTION RISK; META ANALYSIS; PAPILLOMAVIRUS INFECTION; PERSISTENT INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL BEHAVIOR; SYSTEMATIC REVIEW; VACCINATION; WART VIRUS; ADOLESCENT; ADULT; AGED; EVIDENCE BASED MEDICINE; FEMALE; MASS IMMUNIZATION; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MASS VACCINATION; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84907567485     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2014.0584     Document Type: Article

References (40)

1. Krebs in Deutschland 2009/2010: Robert Koch-Institut, Gesellschaft der Epidemiologischen Krebsregister in Deutschland e.V. 2013.
2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
3. Delere Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, et al.: Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based selfsampling. BMC infectious diseases 2014; 14: 87.
4. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al.: Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. The lancet oncology 2008; 9: 425-34.
5. Gerhardus A: Wie wirksam ist die HPV-Impfung? Dtsch Arztebl 2009; 106: A 330-4.
6. Schiller JT, Castellsague X, Garland SM: A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30: F123-38.
7. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al.: Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31: H1-31.
8. Nohynek H, Wichmann O, D Ancona F, Gatekeepers VN: National Advisory Groups and their role in immunization policy-making processes in European countries. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2013; 19: 1096-105.
9. Rambout L, Hopkins L, Hutton B, Fergusson D: Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne 2007; 177: 469-79.
10. La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W: HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 2007; 25: 8352-8.
11. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR: Efficacy of human papillomavirus vaccines: a systematic quantitative review. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 2009; 19: 1166-76.
12. Lu B, Kumar A, Castellsague X, Giuliano AR: Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review &meta-analysis. BMC infectious diseases 2011; 11: 13.
13. Rey-Ares L, Ciapponi A, Pichon-Riviere A: Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: systematic review and meta-analysis. Archivos argentinos de pediatria 2012; 110: 483-9.
14. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al.: Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. The Lancet infectious diseases 2012; 12: 781-9.
15. Robert Koch-Institut: Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomvieren (HPV) für Mädchen von 12 bis 17 Jahren-Empfehlung und Begründung 2007.
16. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
17. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al.: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
18. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al.: GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology 2011; 64: 383-94.
19. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al.: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65.
20. De Carvalho N, Teixeira J, Roteli-Martins CM, et al.: Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28: 6247-55.
21. Garland SM, Hernandez-Avila M, Wheeler CM, et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. The New England journal of medicine 2007; 356: 1928-43.
22. Future II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. The New England journal of medicine 2007; 356: 1915-27.
23. Herrero R, Wacholder S, Rodriguez AC, et al.: Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer discovery 2011; 1: 408-19.
24. Konno R, Tamura S, Dobbelaere K, Yoshikawa H: Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 doubleblind, randomized controlled trial. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 2010; 20: 847-55.
25. Paavonen J, Jenkins D, Bosch FX, et al.: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70.
26. Paavonen J, Naud P, Salmeron J, et al.: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
27. Villa LL, Costa RL, Petta CA, et al.: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebocontrolled multicentre phase II efficacy trial. The lancet oncology 2005; 6: 271-8.
28. Villa LL, Costa RL, Petta CA, et al.: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. British journal of cancer. 2006; 95: 1459-66.
29. Brotherton JM, Fridman M, May CL: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377: 2085-92.
30. Kahn JA, Brown DR, Ding L, et al.: Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics 2012; 130: e249-56.
31. Mesher D, Soldan K, Howell-Jones R, et al.: Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013; 32: 26-32.
32. Niccolai LM, Russ C, Julian PJ, et al.: Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty. Cancer 2013; 119: 3052-8.
33. Powell SE, Hariri S, Steinau M, et al.: Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012; 31: 109-13.
34. Crowe E, Pandeya N, Brotherton JM, et al.: Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. Bmj 2014; 348: g1458.
35. Olsson SE, Villa LL, Costa RL, et al.: Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25: 4931-9.
36. Kjaer SK, Chackerian B, van den Brule AJ, et al.: High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer epidemiology, biomarkers &prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001; 10: 101-6.
37. Noronha AS, Markowitz LE, Dunne EF: Systematic review of human papillomavirus vaccine coadministration. Vaccine 2014; 32: 2670-4.
38. Duclos P, Durrheim DN, Reingold AL, Bhutta ZA, Vannice K, Rees H: Developing evidence-based immunization recommendations and GRADE. Vaccine 2012; 31: 12-9.
39. Ahmed F, Temte JL, Campos-Outcalt D, Schunemann HJ, Group AEBRW: Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine 2011; 29: 9171-6.
40. Ständige Impfkommission am Robert Koch-institut (STIKO): Standardvorgehensweise (SOP). www.stiko.de/DE/Content/Kommission/STIKO/Aufgaben-Methoden/methoden-node.html. Last accessed on 23 October 2013.